Assessing a New Epstein-Barr Virus C Promoter Methylation Test for Diagnosing Nasopharyngeal Carcinoma

What this Trial Is About

Researchers are evaluating a new diagnostic kit that detects Epstein-Barr virus EBV C promoter methylation to help diagnose nasopharyngeal carcinoma. This observational study includes participants who have symptoms or conditions that suggest nasopharyngeal carcinoma or need to be differentiated from it. The goal is to assess how well this methylation detection kit works compared to other standard EBV tests and biopsy results. All participants will undergo diagnostic tests including VCA-IgA, EBNA1-IgA, and EBV-DNA assays. Nasopharyngeal swab samples will be analyzed for EBV C promoter methylation using the new detection kit. A confirmatory biopsy will be performed on all patients to establish a definitive diagnosis. The study aims to compare the diagnostic accuracy of the methylation detection kit with existing tests over a period of up to four weeks from enrollment. Participants will be involved in multiple diagnostic tests and a biopsy to confirm their diagnosis. Researchers will evaluate the sensitivity, specificity, and agreement between the methylation detection kit and other EBV-related tests. The study will also analyze the concordance between different test reagents and sequencing methods. Participant involvement lasts up to four weeks from enrollment to final diagnosis, with careful monitoring of test results and biopsy findings.

Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma